Could low-cost leprosy drug clofazimine be repurposed for COVID-19?

Scientists pointed to clofazimine, a low-cost leprosy drug first approved by the FDA in 1986, as a possible COVID-19 drug after finding promising anti-coronavirus activity in hamsters.

Decades-Old Leprosy Drug Inhibits Coronaviruses, May Treat COVID-19

In an effort to find new treatments for COVID-19 that could be made available quickly, researchers searched through FDA-approved drugs to identify candidates that may inhibit SARS-CoV-2 replication. Researchers found that a decades-old anti-leprosy drug exhibits potent antiviral activities against many coronaviruses—including SARS-CoV-2.

In Pancreatic Cancer, New Biomarker May Predict Benefit of Tumor-Penetrating PeptideIn Pancreatic Cancer, New Biomarker May Predict Benefit of Tumor-Penetrating Peptide

In experiments with models of pancreatic cancer, a cyclic peptide called iRGD was found to penetrate tumors via a molecular pathway mediated by β5 integrin. This protein may serve as a useful biomarker, one that could indicate which patients will respond best to iRGD-combination therapy.

Evan Snyder named Fellow of the American Institute for Medical and Biological Engineering

Renowned stem cell researcher recognized by his peers for seminal contributions to regenerative medicine.

How a 1960s discovery in Yellowstone made millions of COVID-19 PCR tests possible

Tom Brock started the research that would go on to revolutionize the field of biology – and pave the road to the development of the gold-standard COVID-19 tests used to fight a pandemic – with a question.